FDA Advisory Panel Backs GRAIL Galleri Cancer Blood Test Despite Efficacy Doubts

A specialized advisory committee to the Food and Drug Administration has recommended approving the Galleri multi-cancer blood test developed by biotechnology firm GRAIL. The regulatory advisory panel cast a series of recommendations on September 23, 2026, marking a critical first step toward potential commercial rollout. Advisory committee recommendations do not bind the agency, and the FDA has not yet announced when it will make a decision. However, panel members urged caution, recommending that federal authorities remove the designation early from the test's official multi-cancer early detection branding.

Epigenetic Profiling and Diagnostic Specificity

The screening platform evaluates circulating cell-free DNA fragments within blood samples, screening for more than 50 distinct cancer types in a single blood draw. By identifying distinct methylation tags on circulating tumor DNA through machine-learning algorithms, the test seeks to detect malignant signals before clinical symptoms emerge. Targeted conditions encompass 12 lethal malignancies that collectively account for nearly two-thirds of American cancer fatalities, including pancreatic and lung neoplasms. Clinical investigations demonstrate an exceptionally low false-positive rate of approximately 0.5%, meaning only one out of every 200 screened individuals receives an erroneous finding. That precision yielded a 52% positive predictive value across three successive screening years, ensuring that more than half of flagged individuals subsequently received cancer diagnoses.

Early Detection Gaps and Missing Mortality Benefits

Despite high tissue-of-origin accuracy, the chair of the American Cancer Society's screening guideline development group wrote that clinical trial data reveal substantial limitations. Across a validation study evaluating 32,000 adult participants aged 50 and older in the United States, clinicians diagnosed cancer in roughly 0.5% of subjects, representing 173 individuals. While the algorithm predicted primary anatomical tumor origin in 91% of diagnosed patients, it missed 69% of cancers across all disease stages, registering an aggregate detection rate under 31%. Crucially, the platform detected early-stage malignancies at a modest 21% sensitivity rate, failing to capture almost 80% of localized tumors where intervention remains most curable. Among patients with detected malignancies, 60% presented with early-stage disease, an outcome virtually indistinguishable from conventional routine diagnostic screening.

Regulatory Voting Breakdown and Healthcare Costs

The FDA advisory panel demonstrated divisions across three formal evaluative votes regarding clinical safety and effectiveness. Panelists voted unanimously 10-0 affirming procedural safety, observing that merely 0.6% of participants underwent subsequent invasive procedures without suffering serious complications. Members then voted 6-4 endorsing diagnostic effectiveness, though several affirmative ballots required removing the early detection claim from commercial packaging. A final 7-2 vote with one abstention concluded that clinical benefits outweighed risks, despite concerns that the platform failed to prove reductions in late-stage disease or overall mortality. With the Galleri test currently priced at $949 out of pocket and lacking guaranteed Medicare reimbursement, medical leaders advise patients to maintain proven routine cancer screenings. The Food and Drug Administration will review the advisory panel recommendations to issue a final decision regarding the premarket approval application submitted on January 29, 2026, according to Medpath News.